Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Makefield Therapeutics Licenses Patent Rights Covering Its Hybrid Nanoparticle Delivery Platform from Albert Einstein College of Medicine

Abstract:
Uses Include Topical Antimicrobial and Erectile Dysfunction Therapies

Makefield Therapeutics Licenses Patent Rights Covering Its Hybrid Nanoparticle Delivery Platform from Albert Einstein College of Medicine

Newtown, PA | Posted on December 21st, 2009

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform. Makefield Therapeutics is utilizing two different topical formulations of the nitric oxide (NO)-containing nanoparticles in its therapeutic development programs: an antimicrobial for the treatment of drug resistant skin and soft tissue infections; and a topical treatment for Erectile Dysfunction (ED) in men unresponsive or dissatisfied with currently available oral drug treatments.

"Nitric oxide, Science Magazine's 1992 ‘Molecule of the Year,' has been the focus of immense medical and scientific exploration," said Robert Towarnicki, president and chief executive officer of Makefield Therapeutics "Until now, however, the difficulty of conveniently and effectively delivering the gas to targeted tissues has limited the therapeutic application of nitric oxide. The inventors at Einstein, led by Joel Friedman, MD, PhD, have developed a novel method for storing and delivering nitric oxide in a therapeutically relevant manner, through the use of biodegradable nanoparticles constructed of ‘Generally Recognized as Safe' (GRAS) components. We are very pleased to gain access to this promising drug delivery platform, for which the inventors have already published proof-of-concept in several very high value applications."

Mr. Towarnicki noted that multiple, published peer-reviewed articles have demonstrated in animal models the therapeutic potential of the nitric oxide-containing nanoparticles, both as a broad-spectrum antimicrobial and as a topical treatment for erectile dysfunction. Makefield Therapeutics plans to develop these two lead indications commercially and expand the uses of the technology to address other therapeutic applications where the Hybrid Nanoparticle™ technology platform can be enabling.

About the "Hybrid Nanoparticles™ Technology Platform

Hybrid Nanoparticles™ have for the first time enabled the practical delivery of therapeutic amounts of nitric oxide gas (NO) in a local, controlled, and sustained manner. The platform is also capable of delivering peptides, nucleic acids and traditional small molecule pharmaceuticals, both as single therapeutic entities and in combination treatments as well.

Multiple routes of administration including transdermal/topical, oral, intravenous, intraperitoneal, and instillation are possible utilizing this technology. The delivery system is capable of providing for immediate, pulsatile and sustained controlled drug release both locally and systemically.

The delivery system is biodegradable and utilizes excipients that are Generally Recognized as Safe (GRAS), USP-NF listed or previously utilized in medical applications. All of the components of the drug delivery system are commercially available in pharmaceutical grade and the methods of preparation use well-known pharmaceutical unit operations that easily lend themselves to scale up and manufacture.

####

About Makefield Therapeutics
Makefield Therapeutics, Inc., founded in July 2009, is a privately held therapeutics company with two development programs addressing large market opportunities in anti-infectives and the treatment of erectile dysfunction. Both programs are based on an innovative nanoparticle drug delivery platform with the potential to generate a pipeline of additional novel therapeutics.

For more information, please click here

Contacts:
Robert J. Towarnicki
President and CEO

(215) 321-5713

For Media
Joan Kureczka
Kureczka/Martin Associates
(415) 821 2413

Copyright © Makefield Therapeutics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

The power of perovskite: OIST researchers improve perovskite-based technology in the entire energy cycle, from solar cells harnessing power to LED diodes to light the screens of future electronic devices and other lighting applications August 18th, 2017

Gold nanostars and immunotherapy vaccinate mice against cancer: New treatment cures, vaccinates mouse in small proof-of-concept study August 18th, 2017

Researchers printed graphene-like materials with inkjet August 17th, 2017

Candy cane supercapacitor could enable fast charging of mobile phones August 17th, 2017

Products

STMicroelectronics Peps Up Booming Social-Fitness Scene with Smart Motion Sensors for Better Accuracy, Longer Battery Life, and Faster Time to Market January 2nd, 2017

Cutting-edge nanotechnologies are breaking into industries November 18th, 2016

STMicroelectronics’ Semiconductor Chips Contribute to Connected Toothbrush from Oral-B That Sees What You Don’t: Microcontroller and Accelerometer help brushers clean their teeth more effectively October 4th, 2016

Particle Works launches range of high quality magnetic nanoparticles August 31st, 2016

Nanomedicine

Gold nanostars and immunotherapy vaccinate mice against cancer: New treatment cures, vaccinates mouse in small proof-of-concept study August 18th, 2017

Freeze-dried foam soaks up carbon dioxide: Rice University scientists lead effort to make novel 3-D material August 16th, 2017

Gold shines through properties of nano biosensors: Researchers discover that fluorescence in ligand-protected gold nanoclusters is an intrinsic property of the gold particles themselves August 16th, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

Announcements

The power of perovskite: OIST researchers improve perovskite-based technology in the entire energy cycle, from solar cells harnessing power to LED diodes to light the screens of future electronic devices and other lighting applications August 18th, 2017

Gold nanostars and immunotherapy vaccinate mice against cancer: New treatment cures, vaccinates mouse in small proof-of-concept study August 18th, 2017

Researchers printed graphene-like materials with inkjet August 17th, 2017

Candy cane supercapacitor could enable fast charging of mobile phones August 17th, 2017

Patents/IP/Tech Transfer/Licensing

Argonne National Laboratory’s Continuous ALD Technology Licensed Exclusively to Forge Nano July 7th, 2017

Aculon Expands NanoProof® Product Line for Electronics Waterproofing Technology: With growing market opportunities Aculon Launches NanoProof® 8 with Push Through Connectivity™ and NanoProof® DAB a syringe application May 30th, 2017

NREL’s Advanced Atomic Layer Deposition Enables Lithium-Ion Battery Technology: May 10th, 2017

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project